AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...
Guardado en:
Autores principales: | David B Rosen, Kimberly H Harrington, James A Cordeiro, Ling Y Leung, Santosh Putta, Norman Lacayo, George S Laszlo, Chelsea J Gudgeon, Donna E Hogge, Rachael E Hawtin, Alessandra Cesano, Roland B Walter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cdee93bca07145d3b4ee0e020e486f40 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Hien K Duong, et al.
Publicado: (2009) -
Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
por: Ayşe Hilal Eroğlu Küçükdiler, et al.
Publicado: (2021) -
Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
por: Giancarlo Fatobene, et al.
Publicado: (2021) -
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
por: Sonia Jaramillo, et al.
Publicado: (2021) -
Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
por: Thomas X
Publicado: (2014)